Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
To investigate the efficacy and safety of Retlirafusp alfa in combination with chemotherapy or fluzoparib for early-stage and advanced triple-negative breast cancer.
Epistemonikos ID: 5992b0cce3e8e7e3e0ed4b149f0de13841c8b4b4
First added on: Aug 08, 2026